The bioavailability of dTRIM24 for in vivo assessment remains undocumented; thus, we assayed dTRIM24 (kind gift of L. Gechijian, N. Gray and J. Bradner) and its chemical enantiomeric negative control (eTRIM24) using TRIM24-driven primary carcinosarcoma cell lines and control cell line 823. The gene discussed is TRIM24; the disease is carcinosarcoma.